Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Breast Cancer treatment details. Hormone. Hospital Universitario Arnau de Vilanova, Lleida, Spain



Survival: 19.9 months
   
Toxicity Grade: 4
   
Treatments: Hormone
   
Drugs:
Country: Spain
   
City/State/Province: Lleida
   
Hospital: Hospital Universitario Arnau de Vilanova
   
Journal: Link
   
Date: 6/2011

Description:
Patients:
This study involved postmenopausal women with advanced breast cancer who were divided into 2 separate treatment groups. Group A had 51 patients with a median age of 71.6 years. Group B had 52 patients with a median age of 72.6 years.

Treatment:
Patients in group A were treated with the hormone exemestane, which is classified as an aromatase inhibitor and blocks the production of proteins needed for tumor growth.

Patients in group B were treated with the hormone anastrozole, which is also an aromatase inhibitor that blocks the production of proteins needed for tumor growth.

Toxicities:
The most severe toxicity in group A was of grade 4. Grade 3-4 adverse events included hypertension, shortness of breath, and constipation.

The most severe toxicity in group B was of grade 4. Grade 3-4 adverse events included bone pain and shortness of breath.

Results:
The median overall survival for groups A and B was 19.9 and 48.3 months, respectively.

Support:
This study was supported by the pharmaceutical company Pfizer.

Correspondence: Dr. Antonio Llombart-Cussac; email: allombart@arnau.scs.es

E-mail to a Friend Email Physician More Information